Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Myeloma and Plasma Cell Disorders

Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study

Leukemia volume 15, pages 846–854 (2001)Cite this article

Abstract

Eight multiple myeloma patients participated in a phase I trial evaluating the feasibility and safety of subcutaneous vaccination with adenovirus engineered, autologous plasma cells after high-dose therapy. Plasma cells were concentrated from bone marrow harvests by negative selection and high gradient magnetic separation. The mean plasma cell yield was 2.61 × 108. Transgene expression measured 48 h after plasma cell infection with an IL-2 expressing adenovirus averaged 2.95 ng/ml/106 cells. Vaccine production was successful for 88% of patients. Two months after high-dose therapy, six patients received from one to five injections of 3.5–9.0 × 107 cells/vaccine. Vaccines were well tolerated with only minor systemic symptoms reported. Injection with tumor cells induced a local inflammatory response consisting predominantly of CD8+ and/or TIA-1+ T-lymphocytes. Myeloma specific anti-tumor responses, assessed by interferon-γ (IFN-γ) release and cytotoxic T cell killing of autologous tumor cells, were not enhanced after vaccination in one evaluable patient. Clinical response, manifested as a decrease in serum paraprotein, was not observed in the one patient who had measurable disease at the time of vaccination. These results demonstrate that the generation of adenovector modified plasma cell vaccines is technically feasible and can be safely administered post-transplant. Further studies of immunlogic and clinical efficacy are required.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Attal M, Harouseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R . A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome N Engl J Med 1996 335: 91–97

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Garthon G . Bone marrow transplantation in multiple myeloma Bone Marrow Transplant 1991 7: 71–79

    CAS  PubMed  Google Scholar 

  3. Abraham R, Chen C, Tsang R, Simpson D, Murray C, Davidson M, Meharchand J, Sutton DM, Crump RM, Keating A, Stewart AK . Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma Bone Marrow Transplant 1999 24: 1291–1297

    Article  CAS  PubMed  Google Scholar 

  4. Anderson KC, Andersen J, Soiffer R, Freedman AS, Rabinowe SN, Robertson MJ, Spector N, Blake K, Murray C, Freeman A, Coral F, Marcus KC, Mauch P, Nadler LM, Ritz J . Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma Blood 1993 82: 2568–2576

    CAS  PubMed  Google Scholar 

  5. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J . Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma Blood 1999 93: 1858–1868

    CAS  PubMed  Google Scholar 

  6. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle Blood 1997 87: 1196–1198

    Google Scholar 

  7. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ . Graft-verus-myeloma effect in two cases Lancet 1996 347: 800–801

    Article  CAS  PubMed  Google Scholar 

  8. Kwak LW, Taub DD, Duffery L, Bensinger WI, Bryant EM, Reynolds CW, Longo DL . Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor Lancet 1995 345: 1016–1020

    Article  CAS  PubMed  Google Scholar 

  9. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden U, Lefvert AK, Holm G, Mellstedt H . Idiotype immunization combined with granulocyte-macrophage colony stimulating factor in myeloma patients induced type 1, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses Blood 1998 91: 2459–2466

    CAS  PubMed  Google Scholar 

  10. Wen YJ, Ling M, Bailey-Wood R, Lim SH . Idiotype protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma Clin Cancer Res 1998 4: 957–962

    CAS  PubMed  Google Scholar 

  11. Bergenbrant S, Yi Q, Osterborg A, Bjorkholm M, Osby E, Mellstedt H, Lefvert AK, Holm G . Modulation of anti-idiotype immune response by immunization with the autologous M-component protein in multiple myeloma patients Br J Haematol 1996 92: 840–846

    Article  CAS  PubMed  Google Scholar 

  12. Van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann R, Andre M, Rovoet C, Doyen C, Spagnoli GC, Bakkus M, Thielemans K, Boon T . Genes encoding tumor-specific antigens are expressed in human myeloma cells Blood 1999 94: 1156–1164

    CAS  PubMed  Google Scholar 

  13. Mackenzie MR, Paglieroni TG . Plasma cell antigens in human multiple myeloma J Lab Clin Med 1977 89: 1009–1017

    CAS  PubMed  Google Scholar 

  14. Pardoll DM . Paracrine cytokine adjuvants in cancer immunotherapy Ann Rev Immunol 1995 13: 399–415

    Article  CAS  Google Scholar 

  15. Dranoff G, Mulligan RC . Gene transfer as cancer therapy Adv Immunol 1995 58: 417–454

    Article  CAS  PubMed  Google Scholar 

  16. Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK . Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy Blood 1989 74: 2335–2342

    CAS  PubMed  Google Scholar 

  17. Gottlieb DJ, Prentice HG, Mehta AB, Galazka AR, Heslop HE, Hoffbrand AV, Brenner MK . Malignant plasma cells are sensitive to LAK lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma Br J Haematol 1990 75: 499–505

    Article  CAS  PubMed  Google Scholar 

  18. Rosenberg SA, Lotze MT, Yang JC, Aebersold PA, Lineham WM, Siepp CA, White DE . Experience with the use of high-dose interleukin-2 in the treatment of 652 patients with cancer Ann Surg 1989 210: 474–485

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsky H, Simons J, Karasuyama H, Vogelstein B, Frost P . Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 1990 60: 397–403

    Article  CAS  PubMed  Google Scholar 

  20. Gansbacher B, Zier K, Daniels B, Cronin K, Banerji R, Gilboa E . Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity J Exp Med 1990 172: 1217–1224

    Article  CAS  PubMed  Google Scholar 

  21. Kopantzev E, Roschke V, Rudikoff S . Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma Hum Gene Ther 1998 9: 13–19

    Article  CAS  PubMed  Google Scholar 

  22. Bowman L, Grossman M, Rill D, Brown M, Zhong W, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Kitchingman G, Vanin E, Brenner M . IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma Blood 1998 92: 1941–1949

    CAS  PubMed  Google Scholar 

  23. Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, Dessaureault S, Gallinger S, Cappe D, Wan Y, Addison CL, Moen RC, Gauldie J, Graham FL . Adenoviral-mediated gene delivery of IL-2 in metastatic breat cancer and melanoma: results of a phase 1 clinical trial Gene Therapy 1999 6: 350–363

    Article  CAS  PubMed  Google Scholar 

  24. Kwak LW . Tumor vaccination strategies combined with autologous peripheral stem cell transplantation Ann Oncol 1998 9: (Suppl. 1) S41-S46

    Article  Google Scholar 

  25. Stewart AK, Trudel S, Buckstein R, Dube ID, Nanji S, Nayar R, Dodgson C, Dessureault S, Gallenger S, Grahman FL, Hawley RG, Thomas T, Sutherland DR . Plasma cell vaccine production: negative selective, adenoviral infection and in vivo expression of vector derived interleukin-2 (IL-2) Blood 1997 90: 359a

    Google Scholar 

  26. Massaia M, Borrione P, Battagio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A . Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy Blood 1999 94: 673–683

    CAS  PubMed  Google Scholar 

  27. Reichardt VL, Okada CY, Liso A . Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study Blood 1999 93: 2411–2419

    CAS  PubMed  Google Scholar 

  28. Tarte K, Zhang XG, Legouffe E, Hertog C, Mehtali M, Rossi JF, Klein B . Induced expression of B7–1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells J Immunol 1999 163: 514–524

    CAS  PubMed  Google Scholar 

  29. Sun RX, Lu ZY, Wijdenes J . Large scale and clinical grade purification of syndecan-1+ malignant plasma cells J Immunol Meth 1997 205: 73–79

    Article  CAS  Google Scholar 

  30. Fillola G, Muller C, Raymonde B, Fontanilles AM, Laharrague P, Corberand JX . Isolation of bone marrow plasma cells by negative selection with immunomagnetic beads J Immunol Meth 1996 190: 127–131

    Article  Google Scholar 

  31. Schreiber S, Kampgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Kupcu Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe RE, Voigt T, Weber HA, Pehamberger H, Mertelsmann R, Brocker EB, Wolff K, Stingl G . Immunotherapy of metastatic malignant melanoma by vaccine consisting of autologous interleukin-2 transfected cancer cells: outcome of a phase 1 study Hum Gene Ther 1999 10: 983–993

    Article  CAS  PubMed  Google Scholar 

  32. Palmer K, Moore J, Everard M, Harris JD, Rodgers S, Rees RC, Murray AK, Mascari R, Kirkwood J, Riches PG, Fisher C, Thomas JM, Harries M, Johnston SRD, Collins MKL, Gore ME . Gene therapy with autologous interleukin-2 secreting tumor cells in patients with malignant melanoma Hum Gene Ther 1999 10: 1261–1268

    Article  CAS  PubMed  Google Scholar 

  33. Prince HM, Dessureault S, Gallinger S, Krajden M, Sutherland DR, Addison CL, Zhang Y, Graham FL, Stewart AK . Efficient adenoviral mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance Exp Hematol 1998 26: 27–36

    CAS  PubMed  Google Scholar 

  34. Bashey A, Cantwell MJ, Wierda WG, Kipps TJ . Adenovirus mediated gene transfer induces high-level and selective expression of functional CD154 (CD40 ligand) in primary human myeloma cells and cell lines Blood 1999 94: 179a

    Google Scholar 

Download references

Acknowledgements

This work was supported by the Medical Research Council of Canada, the Myeloma Research Foundation, the McCarty Cancer Foundation and the Nelson Arthur Hyland Foundation.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, The Princess Margaret Hospital, Toronto, Canada

    S Trudel, Z Li, C Dodgson, S Nanji, M Voralia & AK Stewart

  2. Department of Biology and Pathology, McMaster University, Hamilton, Ontario, Canada

    Y Wan, M Hitt, J Gauldie & FL Graham

Authors
  1. S Trudel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Dodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Nanji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Voralia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Hitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Gauldie
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. FL Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. AK Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trudel, S., Li, Z., Dodgson, C. et al. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study. Leukemia 15, 846–854 (2001). https://doi.org/10.1038/sj.leu.2402077

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402077

Keywords

This article is cited by

Search

Advanced search

Quick links